Baseline clinical and laboratory parameters in the study cohorts
. | APS with VTE . | VTE without aPLAs . | aPLAs only . | Healthy . |
|---|---|---|---|---|
| Sample size, no. patients | 57 | 32 | 32 | 8 |
| Age range, y | 34-71 | 31-65 | 41-69 | 29-58 |
| Mean age, y | 61 | 59 | 62 | 48 |
| No. female/no. male | 39/18 | 19/13 | 20/12 | 4/4 |
| Mean age at onset of VTE, y | 53.5 | 50.3 | – | – |
| Mean time of study after thrombosis, d (range) | 88 (71-183) | 78 (59-157) | – | – |
| Incidence of VTE, no./no. total (%) | ||||
| PE | 7/57 (12.2) | 3/32 (9.3) | – | – |
| PE + DVT | 14/57 (24.5) | 8/32 (25) | – | – |
| DVT | 36/57 (63.2) | 21/32 (65.7) | – | – |
| Mean anticardiolipin, GPL (range) | 34.5 (1-106) | 6.3 (2-11) | 32.7 (5-86) | 8.5 (3-12) |
| Mean anti-β2 glycoprotein, GAU/mL (range) | 17.0 (1-72) | 1.0 (1-1) | 16.2 (2-53) | 1.0 (1-1) |
| Lupus anticoagulant, no./no. total (%)* | 45/51 (88.2) | 0/28 (0) | 27/29 (93.1) | 0/8 (0) |
| Inherited thrombophilia, no./no. total (%)† | 3/53 (0.05) | 1/32 (0.03) | 0/30 (0) | – |
| Smoking history, no./no. total (%) | 11/57 (19.2) | 6/32 (18.7) | 7/32 (21.8) | 2/8 (25) |
. | APS with VTE . | VTE without aPLAs . | aPLAs only . | Healthy . |
|---|---|---|---|---|
| Sample size, no. patients | 57 | 32 | 32 | 8 |
| Age range, y | 34-71 | 31-65 | 41-69 | 29-58 |
| Mean age, y | 61 | 59 | 62 | 48 |
| No. female/no. male | 39/18 | 19/13 | 20/12 | 4/4 |
| Mean age at onset of VTE, y | 53.5 | 50.3 | – | – |
| Mean time of study after thrombosis, d (range) | 88 (71-183) | 78 (59-157) | – | – |
| Incidence of VTE, no./no. total (%) | ||||
| PE | 7/57 (12.2) | 3/32 (9.3) | – | – |
| PE + DVT | 14/57 (24.5) | 8/32 (25) | – | – |
| DVT | 36/57 (63.2) | 21/32 (65.7) | – | – |
| Mean anticardiolipin, GPL (range) | 34.5 (1-106) | 6.3 (2-11) | 32.7 (5-86) | 8.5 (3-12) |
| Mean anti-β2 glycoprotein, GAU/mL (range) | 17.0 (1-72) | 1.0 (1-1) | 16.2 (2-53) | 1.0 (1-1) |
| Lupus anticoagulant, no./no. total (%)* | 45/51 (88.2) | 0/28 (0) | 27/29 (93.1) | 0/8 (0) |
| Inherited thrombophilia, no./no. total (%)† | 3/53 (0.05) | 1/32 (0.03) | 0/30 (0) | – |
| Smoking history, no./no. total (%) | 11/57 (19.2) | 6/32 (18.7) | 7/32 (21.8) | 2/8 (25) |
APS indicates antiphospholipid syndrome; VTE, venous thromboembolism; PE, pulmonary embolism; DVT, deep vein thrombosis; aPLAs, antiphospholipid antibodies; and –, not applicable.
n = 116. Based on recommendations from the ISTH, there were 4 criteria for diagnosing a lupus anticoagulant (LA) in our cohorts: (1) demonstration of prolongation of a phospholipid-dependent clotting assay, (2) demonstration using mixing studies or factor assays that an inhibitor is present, (3) demonstration that the inhibitor is phospholipid dependent, and (4) absence of a specific factor inhibitor, such as a factor VIII inhibitor. Based on these criteria, 116 of 129 subjects had LA data
Testing for protein C and S deficiency, antithrombin III deficiency, Leiden factor V, and prothrombin 20210A polymorphisms